# Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

> **NCT07047885** · PHASE1 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 38 (estimated)

## Conditions studied

- Cutaneous T Cell Lymphoma

## Interventions

- **DRUG:** Ropeginterferon alfa-2b

## Key facts

- **NCT ID:** NCT07047885
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07047885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07047885, "Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07047885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*